BRAF and melanoma: The concept of targeting both Raf and MEK is especially true with BRAF inhibitors and melanoma which contain mutations at BRAFV600E due to the negative feedback elicited by downstream ERK which suppresses the sensitivity of the cells to signaling induced by growth factors and Ras activity is low [32].